drugset / Trial / NCT07087795
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes
RandomizedCrossoverQuadruple-blindTreatment
Summary
This study is testing the effect of a new study medicine NNC0194-0499 in type 1 diabetes. The purpose of the study is to compare the effect of NNC0194-0499 on the blood sugar levels of participants with type 1 diabetes when taken in combination with semaglutide or placebo. All participants will receive standard of care insulin treatment. The study will last for about 36 weeks.
Timeline
- Start
- 2025-07-01
- Primary completion
- 2026-09-12
- Completion
- 2026-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zalfermin | Protein / enzyme biologic | — | Subcutaneous |
| Background | Semaglutide | Peptide | — | Subcutaneous |